Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck
β Scribed by Ezra Eddy Wyssam Cohen; Anna B. Halpern; Kristen Kasza; Masha Kocherginsky; Rosalyn Williams; Everett E. Vokes
- Book ID
- 113833214
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 219 KB
- Volume
- 45
- Category
- Article
- ISSN
- 1368-8375
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Background Cumulative evidence implicates the epidermal growth factor receptor (EGFR) as an important therapeutic target in head and neck squamous cell carcinoma (HNSCC). The basis for the lack of correlation between EGFR expression in the HNSCC tumor and clinical responses to EGFR
Epidermal growth factor (EGF) stimulates the growth of several types of epithelial tissues and possesses a strong mitogenic activity that is mediated through its cell surface receptor (EGFR). The aim of this study was to characterize EGFR and measure its levels in head and neck tumors biopsies (70 p
## Abstract The degree of gene amplification for epidermal growth factor receptor (EGFR) and its expression levels were examined in 4 cases of tumor lesions and their cell lines of human squamous cell carcinoma (SCC) of the oral cavity. The amplification was detected in 1 case (ZA), but not signifi